Skip to main content
Clinical Trials/NCT03260478
NCT03260478
Completed
Not Applicable

HEMOglobin Transfusion Threshold in Traumatic Brain Injury OptimizatioN: The HEMOTION Trial

CHU de Quebec-Universite Laval33 sites in 4 countries742 target enrollmentStarted: August 31, 2017Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
CHU de Quebec-Universite Laval
Enrollment
742
Locations
33
Primary Endpoint
extended Glasgow Outcome Scale (GOSe)

Overview

Brief Summary

Most trauma deaths are related to traumatic brain injury (TBI). Although the management of patients has improved, mortality remains unacceptably high, and half of survivors of moderate and severe TBI are left with major functional impairment. Current management guidelines are based on limited evidence and practice is highly variable. Most acutely ill patients with TBI will develop anemia, which may decrease oxygen delivery to a fragile brain. While clinical practice is moving towards transfusing at low hemoglobin (Hb) levels, experts have expressed concerns regarding restrictive strategies, which may adversely affect clinical outcomes in TBI. Our primary objective is to evaluate the effect of red blood cell (RBC) transfusion thresholds on neurological functional outcome. We hypothesize that a liberal transfusion strategy improves outcomes compared to a restrictive strategy.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

Open-label with blinded outcome evaluation.

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Acute moderate to severe blunt TBI
  • Glasgow Coma Score \[GCS\] ≤ 12
  • Hb level ≤ 100 g/L

Exclusion Criteria

  • Patient has received transfusion after ICU admission
  • Contraindications or known objection to transfusions
  • Glasgow Coma Scale (GCS) of 3 with dilated fixed pupils.
  • Patient is brain dead
  • Active life-threatening bleeding with hemorrhagic shock or requiring urgent surgical procedure
  • A decision to withold or withdraw life-sustaining therapies was made
  • No fixed address

Outcomes

Primary Outcomes

extended Glasgow Outcome Scale (GOSe)

Time Frame: 6 months

Assessment of neurological outcome by the extended Glasgow Outcome Scale (GOSe)

Secondary Outcomes

  • Quality of life (EQ-5D)(6 months)
  • Quality of life (Qolibri questionnaires)(6 months)
  • Mortality(ICU, Hospital and at 6 months)
  • Functional Independence Measure (FIM)(6 months)
  • Depression (PHQ-9)(6 months)

Investigators

Sponsor
CHU de Quebec-Universite Laval
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr Alexis Turgeon

Professor

CHU de Quebec-Universite Laval

Study Sites (33)

Loading locations...

Similar Trials